Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Sep-Oct;99(5):778-780.
doi: 10.1016/j.abd.2023.08.017. Epub 2024 Jun 13.

Bullous pemphigoid successfully treated with dupilumab

Daniela de Abreu E Silva Martinez  1 , Amanda de Freitas Sampaio Periquito  2 , Graciela Galva Roa  2 , João Pedro Lupi  3 , Curt Mafra Treu  2 , Omar Lupi  4
Affiliations
Case Reports

Bullous pemphigoid successfully treated with dupilumab

Daniela de Abreu E Silva Martinez et al. An Bras Dermatol. 2024 Sep-Oct.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Isolated tight blisters can be seen on the right thigh.
Figure 2
Figure 2
Erosions on the trunk and buttocks.
Figure 3
Figure 3
Hematoxylin & eosin, 100x. Revealing subepidermal blister formation with eosinophilic infiltrate.
Figure 4
Figure 4
Lesions resolved with post-inflammatory hyperpigmantation.
See this image and copyright information in PMC

References

    1. Russo R., Capurro N., Cozzani E., Parodi A. Use of dupilumab in bullous pemphigoid: where are we now? J Clin Med. 2022;11:3367. - PMC - PubMed
    1. Zhang Y., Xu Q., Chen L., Chen J., Zhang J., Zou Y., Gong T., Ji C. Efficacy and safety of dupilumab in moderate-to-severe bullous pemphigoid. Front Immunol. 2021;12 - PMC - PubMed
    1. Zhang L., Chen Z., Wang L., Luo X. Bullous pemphigoid: the role of type 2 inflammation in its pathogenesis and the prospect of targeted therapy. Front Immunol. 2023;14 - PMC - PubMed
    1. Zhou A.E., Shao K., Ferenczi K., Adalsteinsson J.A. Recalcitrant bullous pemphigoid responsive to dupilumab in an adolescent patient. JAAD Case Rep. 2022;29:149–151. - PMC - PubMed
    1. Santi C.G., Gripp A.C., Roselino A.M., Mello D.S., Gordilho J.O., Marsillac P.F., et al. Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology. An Bras Dermatol. 2019;94:33–47. - PMC - PubMed

Substances

LinkOut - more resources